U.S. Markets closed

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8500+0.1000 (+2.67%)
At close: 4:00PM EDT

BELLUS Health Inc.

275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
450 680 4500

Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Mr. Roberto Francesco BelliniPres, CEO & Director441.61kN/A1980
Mr. François Desjardins C.A., CPA, CPA, CAVP of Fin.180.29kN/A1963
Mr. Ramzi BenamarChief Financial Officer340.75kN/A1973
Dr. Denis GarceauSr. VP of Drug Devel.277.76kN/A1957
Dr. Catherine M. BonuccelliChief Medical Officer461.65kN/A1958
Mr. Daniel MatthewsDirector of Investor Relations & CommunicationsN/AN/AN/A
Mr. Sebastien RoyCorp. Sec.N/AN/A1976
Mr. Tony MatzouranisVP of Bus. Devel.N/AN/A1973
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

Corporate Governance

BELLUS Health Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.